Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia (HAYATE)
jRCT2051210041Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD8233 in dyslipidemia and hypercholesterolemia (8 arms), sponsored by AstraZeneca. Primary endpoints: Part A: Safety and tolerability of AZD8233 and Part B: Effect of AZD8233 on LDL-C. Started Jan 2021; status: completed.
02
Drugs
AZD8233
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on jRCT2051210041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210041.